Aluminum Oxide Calcium Silicate Ferrosoferric Phos

證據等級: L5

預測適應症: 0 個

Multi-Mineral Compound: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This submission contains a multi-component mineral mixture (Aluminum Oxide; Calcium Silicate; Ferrosoferric Phosphate; Iron; Magnesium Chloride; Phosphorus; Silicon Dioxide; Sodium Nitrate; Zinc) with no registered original indications and no DrugBank identifier. The TxGNN model returned no predicted new indications for this compound, and the substance is not currently marketed in Taiwan (0 active licenses). Due to critical data gaps across all evaluation domains, a full repurposing analysis cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	Not available
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	Below L5 (no predictions, no studies)
US Market Status	Not marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No mechanistic analysis can be performed at this stage for three reasons:

First, the submitted compound is not a single active pharmaceutical ingredient but a nine-component inorganic mineral mixture (aluminium oxide, calcium silicate, ferrosoferric phosphate, elemental iron, magnesium chloride, phosphorus, silicon dioxide, sodium nitrate, and zinc). Such mixtures are typically encountered in geological materials, soil amendments, or uncharacterised mineral supplements — not as registered drug entities. The lack of a DrugBank ID confirms that no standard pharmaceutical identity has been established.

Second, the original MOA field is marked as a data gap, and the original indications array is empty. Without a therapeutic context, it is impossible to draw analogies to new disease areas.

Third, the TxGNN knowledge-graph model requires a matched DrugBank node as input. Because this compound has no DrugBank ID, it could not be embedded in the knowledge graph, and consequently no disease predictions were generated. This is an expected upstream failure, not a model result.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

This compound has no active licenses on record. No authorization table can be generated.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields — key warnings, contraindications, and drug–drug interactions — returned no data for this compound.)

Conclusion and Next Steps

Decision: Hold

Rationale: The compound as submitted cannot be evaluated for drug repurposing because it lacks the foundational identifiers (DrugBank ID, original indication, MOA) required for TxGNN prediction and mechanistic reasoning; no indications were predicted, and no supporting clinical or literature evidence exists.

To proceed, the following is needed:

Clarify compound identity: Determine whether this multi-mineral mixture corresponds to a recognised pharmaceutical product, dietary supplement, or industrial material. If it is a formulation, identify the primary active ingredient and obtain its DrugBank ID.
Resolve DG001 (Blocking): Retrieve the full prescribing information / package insert from the relevant regulatory authority to populate warnings and contraindications before any safety screening can proceed.
Resolve DG002 (High): Query the DrugBank API with the confirmed single-ingredient INN to obtain MOA data, enabling mechanistic plausibility analysis.
Re-run TxGNN pipeline: Once a valid DrugBank node ID is confirmed, re-submit the corrected drug identifier to the TxGNN prediction pipeline to generate candidate indications.
Confirm regulatory scope: Clarify which market(s) this compound is intended for and whether it falls under drug, supplement, or non-pharmaceutical regulation before proceeding with clinical repurposing strategy.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.